Gilead opting against IDE397 is still good news for Ideaya.
ApexOnco Front Page
Recent articles
Progression-free and overall survival data from Companion-002 are due this quarter.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Just when investors thought things couldn't get any worse, they do.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
